Puma Biotechnology (PBYI) Debt to Equity: 2019-2025
Historic Debt to Equity for Puma Biotechnology (PBYI) over the last 6 years, with Sep 2025 value amounting to $0.29.
- Puma Biotechnology's Debt to Equity fell 73.37% to $0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.29, marking a year-over-year decrease of 73.37%. This contributed to the annual value of $0.73 for FY2024, which is 60.97% down from last year.
- Latest data reveals that Puma Biotechnology reported Debt to Equity of $0.29 as of Q3 2025, which was down 31.73% from $0.43 recorded in Q2 2025.
- Puma Biotechnology's 5-year Debt to Equity high stood at $13.63 for Q1 2022, and its period low was -$39.69 during Q4 2021.
- Its 3-year average for Debt to Equity is $1.67, with a median of $1.84 in 2024.
- Within the past 5 years, the most significant YoY rise in Puma Biotechnology's Debt to Equity was 456.65% (2021), while the steepest drop was 140.28% (2021).
- Quarterly analysis of 5 years shows Puma Biotechnology's Debt to Equity stood at -$39.69 in 2021, then soared by 111.46% to $4.55 in 2022, then tumbled by 59.01% to $1.86 in 2023, then tumbled by 60.97% to $0.73 in 2024, then slumped by 73.37% to $0.29 in 2025.
- Its Debt to Equity stands at $0.29 for Q3 2025, versus $0.43 for Q2 2025 and $0.58 for Q1 2025.